|
KMID : 1141720160040020006
|
|
폐쇄성폐질환
2016 Volume.4 No. 2 p.6 ~ p.6
|
|
|
|
|
Kim Jin-Woo
|
|
|
Abstract
|
|
|
|
Biomarker defines as “a characteristic (or variable) that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.” Clinically biomarkers can be used for diagnosis, prognosis, severity assessment, staging of disease, and for monitoring disease activity or clinical response to therapeutic interventions. There are several promising biomarkers on the horizon. In the sputum, eosinophilia is a promising biomarker for COPD exacerbation and steroid responsiveness. In the blood, promising plasma proteins include fibrinogen, CRP, IL-6 and CC-16. Additionally, blood eosinophilia (＞2% of total cell count) may be a good predictor of steroid responsiveness in acute exacerbations. Evolving technology in gene sequencing, micro-RNA interrogation, and robust, high throughput proteomics, coupled with large scale cohort studies in COPD will enable identification, validation and qualification of even better biomarkers in the near future for the diagnosis, prognosis and monitoring (of therapeutics) in COPD.
|
|
|
KEYWORD
|
|
|
COPD, Biomarker
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|